Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Viridian Therapeutics Inc has a consensus price target of $38.73 based on the ratings of 18 analysts. The high is $61 issued by BTIG on September 26, 2024. The low is $20 issued by B. Riley Securities on May 9, 2024. The 3 most-recent analyst ratings were released by Needham, Wells Fargo, and RBC Capital on January 7, 2025, December 19, 2024, and December 17, 2024, respectively. With an average price target of $37.33 between Needham, Wells Fargo, and RBC Capital, there's an implied 158.54% upside for Viridian Therapeutics Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
01/07/2025 | Buy Now | 163.16% | Needham | Serge Belanger70% | $38 → $38 | Reiterates | Buy → Buy | Get Alert |
12/19/2024 | Buy Now | 86.98% | Wells Fargo | Derek Archila58% | → $27 | Downgrade | Overweight → Equal-Weight | Get Alert |
12/17/2024 | Buy Now | 225.48% | RBC Capital | Gregory Renza47% | $44 → $47 | Maintains | Outperform | Get Alert |
12/17/2024 | Buy Now | 135.46% | HC Wainwright & Co. | Douglas Tsao52% | $34 → $34 | Reiterates | Buy → Buy | Get Alert |
12/16/2024 | Buy Now | 135.46% | HC Wainwright & Co. | Douglas Tsao52% | $34 → $34 | Reiterates | Buy → Buy | Get Alert |
12/05/2024 | Buy Now | 204.71% | RBC Capital | Gregory Renza47% | $44 → $44 | Reiterates | Outperform → Outperform | Get Alert |
11/25/2024 | Buy Now | 163.16% | Needham | Serge Belanger70% | $38 → $38 | Reiterates | Buy → Buy | Get Alert |
11/25/2024 | Buy Now | — | TD Cowen | Joseph Thome34% | — | Initiates | → Buy | Get Alert |
11/14/2024 | Buy Now | 135.46% | HC Wainwright & Co. | Douglas Tsao52% | $27 → $34 | Maintains | Buy | Get Alert |
11/13/2024 | Buy Now | 163.16% | Needham | Serge Belanger70% | $38 → $38 | Reiterates | Buy → Buy | Get Alert |
10/28/2024 | Buy Now | 163.16% | Needham | Serge Belanger70% | $38 → $38 | Reiterates | Buy → Buy | Get Alert |
09/26/2024 | Buy Now | 322.44% | BTIG | Julian Harrison41% | $56 → $61 | Maintains | Buy | Get Alert |
09/19/2024 | Buy Now | 204.71% | RBC Capital | Gregory Renza47% | $44 → $44 | Reiterates | Outperform → Outperform | Get Alert |
09/13/2024 | Buy Now | 204.71% | RBC Capital | Gregory Renza47% | $35 → $44 | Maintains | Outperform | Get Alert |
09/12/2024 | Buy Now | 114.68% | Goldman Sachs | Richard Law45% | $25 → $31 | Maintains | Buy | Get Alert |
09/11/2024 | Buy Now | 163.16% | Needham | Serge Belanger70% | $30 → $38 | Maintains | Buy | Get Alert |
09/10/2024 | Buy Now | 86.98% | HC Wainwright & Co. | Douglas Tsao52% | $27 → $27 | Reiterates | Buy → Buy | Get Alert |
09/10/2024 | Buy Now | 287.81% | BTIG | Julian Harrison41% | $46 → $56 | Maintains | Buy | Get Alert |
08/30/2024 | Buy Now | 107.76% | Needham | Serge Belanger70% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
08/28/2024 | Buy Now | 142.38% | RBC Capital | Gregory Renza47% | $35 → $35 | Reiterates | Outperform → Outperform | Get Alert |
08/15/2024 | Buy Now | 86.98% | HC Wainwright & Co. | Douglas Tsao52% | $27 → $27 | Reiterates | Buy → Buy | Get Alert |
08/12/2024 | Buy Now | 93.91% | Oppenheimer | Leland Gershell69% | $31 → $28 | Reiterates | Outperform → Outperform | Get Alert |
07/29/2024 | Buy Now | 190.86% | Wedbush | Laura Chico47% | $42 → $42 | Reiterates | Outperform → Outperform | Get Alert |
07/16/2024 | Buy Now | 86.98% | HC Wainwright & Co. | Douglas Tsao52% | $27 → $27 | Reiterates | Buy → Buy | Get Alert |
06/11/2024 | Buy Now | — | Wolfe Research | Andy Chen37% | — | Initiates | → Outperform | Get Alert |
06/11/2024 | Buy Now | 107.76% | Needham | Serge Belanger70% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
06/06/2024 | Buy Now | 59.28% | Goldman Sachs | Richard Law45% | → $23 | Initiates | → Buy | Get Alert |
05/09/2024 | Buy Now | 107.76% | Needham | Serge Belanger70% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
05/09/2024 | Buy Now | 86.98% | HC Wainwright & Co. | Douglas Tsao52% | $37 → $27 | Maintains | Buy | Get Alert |
05/09/2024 | Buy Now | 114.68% | Oppenheimer | Leland Gershell69% | $36 → $31 | Maintains | Outperform | Get Alert |
05/09/2024 | Buy Now | — | Ladenburg Thalmann | Michael Higgins47% | — | Downgrade | Buy → Neutral | Get Alert |
05/09/2024 | Buy Now | 38.5% | B. Riley Securities | Kalpit Patel38% | $25 → $20 | Downgrade | Buy → Neutral | Get Alert |
03/21/2024 | Buy Now | 73.13% | B. Riley Securities | Kalpit Patel38% | $29 → $25 | Maintains | Buy | Get Alert |
03/20/2024 | Buy Now | 107.76% | Needham | Serge Belanger70% | $30 → $30 | Maintains | Buy | Get Alert |
02/29/2024 | Buy Now | 156.23% | HC Wainwright & Co. | Douglas Tsao52% | $37 → $37 | Reiterates | Buy → Buy | Get Alert |
02/28/2024 | Buy Now | 107.76% | Needham | Serge Belanger70% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
02/28/2024 | Buy Now | 177.01% | Wedbush | Laura Chico47% | $39 → $40 | Maintains | Outperform | Get Alert |
12/19/2023 | Buy Now | 149.31% | Oppenheimer | Leland Gershell69% | $35 → $36 | Maintains | Outperform | Get Alert |
12/18/2023 | Buy Now | 156.23% | HC Wainwright & Co. | Douglas Tsao52% | $37 → $37 | Reiterates | Buy → Buy | Get Alert |
12/14/2023 | Buy Now | 142.38% | RBC Capital | Gregory Renza47% | $35 → $35 | Reiterates | Outperform → Outperform | Get Alert |
12/04/2023 | Buy Now | 156.23% | Wedbush | Laura Chico47% | → $37 | Reiterates | Outperform → Outperform | Get Alert |
11/14/2023 | Buy Now | 142.38% | RBC Capital | Gregory Renza47% | → $35 | Reiterates | Outperform → Outperform | Get Alert |
11/14/2023 | Buy Now | 163.16% | JMP Securities | Jason Butler55% | $42 → $38 | Maintains | Market Outperform | Get Alert |
10/31/2023 | Buy Now | 142.38% | RBC Capital | Gregory Renza47% | $44 → $35 | Maintains | Outperform | Get Alert |
10/31/2023 | Buy Now | 156.23% | Wedbush | Laura Chico47% | $46 → $37 | Maintains | Outperform | Get Alert |
10/30/2023 | Buy Now | 107.76% | Needham | Serge Belanger70% | $40 → $30 | Maintains | Buy | Get Alert |
09/13/2023 | Buy Now | 177.01% | Stifel | Alex Thompson44% | → $40 | Reiterates | Buy → Buy | Get Alert |
09/13/2023 | Buy Now | 218.56% | Wedbush | Laura Chico47% | → $46 | Reiterates | Outperform → Outperform | Get Alert |
08/10/2023 | Buy Now | 156.23% | HC Wainwright & Co. | Douglas Tsao52% | $40 → $37 | Maintains | Buy | Get Alert |
08/10/2023 | Buy Now | 177.01% | Needham | Serge Belanger70% | $47 → $40 | Maintains | Buy | Get Alert |
08/09/2023 | Buy Now | 190.86% | JMP Securities | Jason Butler55% | $44 → $42 | Maintains | Market Outperform | Get Alert |
08/09/2023 | Buy Now | 204.71% | RBC Capital | Gregory Renza47% | → $44 | Reiterates | Outperform → Outperform | Get Alert |
08/09/2023 | Buy Now | 170.08% | Wells Fargo | — | $46 → $39 | Maintains | Overweight | Get Alert |
08/09/2023 | Buy Now | 142.38% | Oppenheimer | Leland Gershell69% | $40 → $35 | Maintains | Outperform | Get Alert |
07/11/2023 | Buy Now | 211.63% | Wedbush | Laura Chico47% | $48 → $45 | Maintains | Outperform | Get Alert |
07/11/2023 | Buy Now | 204.71% | RBC Capital | Gregory Renza47% | → $44 | Reiterates | Outperform → Outperform | Get Alert |
07/11/2023 | Buy Now | 204.71% | JMP Securities | Jason Butler55% | → $44 | Reiterates | Market Outperform → Market Outperform | Get Alert |
07/11/2023 | Buy Now | 225.48% | Needham | Serge Belanger70% | → $47 | Reiterates | Buy → Buy | Get Alert |
07/11/2023 | Buy Now | 177.01% | HC Wainwright & Co. | Douglas Tsao52% | → $40 | Reiterates | Buy → Buy | Get Alert |
06/14/2023 | Buy Now | 218.56% | BTIG | Julian Harrison41% | → $46 | Initiates | → Buy | Get Alert |
06/14/2023 | Buy Now | 253.19% | Credit Suisse | Tiago Fauth42% | → $51 | Assumes | → Outperform | Get Alert |
05/30/2023 | Buy Now | 204.71% | RBC Capital | Gregory Renza47% | → $44 | Initiates | → Outperform | Get Alert |
05/10/2023 | Buy Now | 177.01% | Oppenheimer | Leland Gershell69% | $45 → $40 | Maintains | Outperform | Get Alert |
05/10/2023 | Buy Now | 232.41% | Wedbush | Laura Chico47% | $46 → $48 | Maintains | Outperform | Get Alert |
05/10/2023 | Buy Now | 253.19% | Credit Suisse | Tiago Fauth42% | → $51 | Reiterates | → Outperform | Get Alert |
05/10/2023 | Buy Now | 204.71% | JMP Securities | Jason Butler55% | $46 → $44 | Maintains | Market Outperform | Get Alert |
05/10/2023 | Buy Now | 177.01% | HC Wainwright & Co. | Douglas Tsao52% | → $40 | Reiterates | → Buy | Get Alert |
04/17/2023 | Buy Now | 218.56% | Wells Fargo | — | → $46 | Initiates | → Overweight | Get Alert |
04/10/2023 | Buy Now | 225.48% | Needham | Serge Belanger70% | → $47 | Reiterates | → Buy | Get Alert |
03/30/2023 | Buy Now | 239.34% | Stifel | Alex Thompson44% | → $49 | Initiates | → Buy | Get Alert |
03/09/2023 | Buy Now | 177.01% | Ladenburg Thalmann | Michael Higgins47% | → $40 | Reiterates | → Buy | Get Alert |
03/09/2023 | Buy Now | 177.01% | HC Wainwright & Co. | Douglas Tsao52% | $35 → $40 | Maintains | Buy | Get Alert |
02/07/2023 | Buy Now | 142.38% | HC Wainwright & Co. | Douglas Tsao52% | → $35 | Reiterates | → Buy | Get Alert |
01/09/2023 | Buy Now | 211.63% | SVB Leerink | Thomas Smith33% | $40 → $45 | Maintains | Outperform | Get Alert |
12/19/2022 | Buy Now | 211.63% | Needham | Serge Belanger70% | → $45 | Initiates | → Buy | Get Alert |
12/16/2022 | Buy Now | 253.19% | Credit Suisse | Tiago Fauth42% | → $51 | Initiates | → Outperform | Get Alert |
12/01/2022 | Buy Now | 142.38% | HC Wainwright & Co. | Douglas Tsao52% | → $35 | Initiates | → Buy | Get Alert |
11/15/2022 | Buy Now | 218.56% | JMP Securities | Jason Butler55% | $47 → $46 | Maintains | Market Outperform | Get Alert |
08/16/2022 | Buy Now | 177.01% | Ladenburg Thalmann | Michael Higgins47% | $33 → $40 | Maintains | Buy | Get Alert |
08/15/2022 | Buy Now | 177.01% | SVB Leerink | Mike Kratky64% | $32 → $40 | Maintains | Outperform | Get Alert |
06/23/2022 | Buy Now | 73.13% | B. Riley Securities | Kalpit Patel38% | → $25 | Initiates | → Buy | Get Alert |
The latest price target for Viridian Therapeutics (NASDAQ:VRDN) was reported by Needham on January 7, 2025. The analyst firm set a price target for $38.00 expecting VRDN to rise to within 12 months (a possible 163.16% upside). 32 analyst firms have reported ratings in the last year.
The latest analyst rating for Viridian Therapeutics (NASDAQ:VRDN) was provided by Needham, and Viridian Therapeutics reiterated their buy rating.
There is no last upgrade for Viridian Therapeutics
The last downgrade for Viridian Therapeutics Inc happened on December 19, 2024 when Wells Fargo changed their price target from N/A to $27 for Viridian Therapeutics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Viridian Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Viridian Therapeutics was filed on January 7, 2025 so you should expect the next rating to be made available sometime around January 7, 2026.
While ratings are subjective and will change, the latest Viridian Therapeutics (VRDN) rating was a reiterated with a price target of $38.00 to $38.00. The current price Viridian Therapeutics (VRDN) is trading at is $14.44, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.